Equities analysts expect Emergent Biosolutions Inc (NYSE:EBS) to report $209.30 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Emergent Biosolutions’ earnings, with estimates ranging from $208.60 million to $210.00 million. Emergent Biosolutions posted sales of $100.77 million during the same quarter last year, which suggests a positive year over year growth rate of 107.7%. The firm is scheduled to report its next quarterly earnings report on Thursday, August 2nd.
According to Zacks, analysts expect that Emergent Biosolutions will report full-year sales of $739.24 million for the current fiscal year, with estimates ranging from $730.90 million to $750.20 million. For the next financial year, analysts expect that the business will post sales of $789.09 million per share, with estimates ranging from $739.70 million to $837.40 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.25). Emergent Biosolutions had a return on equity of 10.39% and a net margin of 11.96%. The firm had revenue of $117.80 million during the quarter, compared to analyst estimates of $140.42 million. During the same quarter in the prior year, the company posted $0.23 EPS. The company’s quarterly revenue was up .8% on a year-over-year basis.
A number of research firms recently commented on EBS. Cantor Fitzgerald restated an “overweight” rating on shares of Emergent Biosolutions in a report on Thursday, June 14th. Argus assumed coverage on Emergent Biosolutions in a report on Wednesday, June 13th. They set a “buy” rating and a $62.00 price target on the stock. ValuEngine upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Tuesday, May 1st. Finally, Wells Fargo & Co downgraded Emergent Biosolutions from an “outperform” rating to a “market perform” rating and set a $56.00 price target on the stock. in a report on Tuesday, April 24th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $58.14.
In other Emergent Biosolutions news, Director Ronald Richard sold 7,893 shares of the stock in a transaction that occurred on Tuesday, April 17th. The stock was sold at an average price of $55.00, for a total transaction of $434,115.00. Following the transaction, the director now owns 31,303 shares in the company, valued at $1,721,665. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kathryn C. Zoon sold 1,377 shares of the stock in a transaction that occurred on Thursday, May 24th. The shares were sold at an average price of $51.15, for a total value of $70,433.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,431 shares of company stock worth $1,611,411. Corporate insiders own 16.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Financial Gravity Companies Inc. bought a new stake in shares of Emergent Biosolutions in the fourth quarter valued at approximately $118,000. Stratos Wealth Partners LTD. bought a new stake in shares of Emergent Biosolutions in the first quarter valued at approximately $134,000. PNC Financial Services Group Inc. boosted its position in shares of Emergent Biosolutions by 108.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 1,482 shares during the period. SG Americas Securities LLC bought a new stake in shares of Emergent Biosolutions in the first quarter valued at approximately $171,000. Finally, LS Investment Advisors LLC boosted its position in shares of Emergent Biosolutions by 183.0% in the fourth quarter. LS Investment Advisors LLC now owns 3,948 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 2,553 shares during the period. 83.07% of the stock is owned by institutional investors.
Emergent Biosolutions traded down $0.50, reaching $50.77, during mid-day trading on Friday, MarketBeat reports. The stock had a trading volume of 286,100 shares, compared to its average volume of 351,845. Emergent Biosolutions has a fifty-two week low of $32.48 and a fifty-two week high of $55.94. The company has a market capitalization of $2.60 billion, a P/E ratio of 26.72, a P/E/G ratio of 1.11 and a beta of 1.30. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.70 and a current ratio of 5.49.
Emergent Biosolutions declared that its Board of Directors has approved a stock repurchase plan on Thursday, March 22nd that authorizes the company to buyback $50.00 million in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.